+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06919939

Study of Epcoritamab Combined With Loncastuximab Tesirine for Treating Relapsed or Refractory Large B-cell Lymphoma

Led by University of Miami · Updated on 2026-10-15

26

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating whether combining two drugs, Loncastuximab Tesirine and Epcoritamab, is tolerable and effective in reducing or eliminating lymphoma cells in people with relapsed or refractory large B-cell lymphoma. This phase 2 study focuses on patients who have previously received therapy for this type of lymphoma and aims to assess safety and treatment response. Participants in the study receive up to four cycles of both Epcoritamab and Loncastuximab Tesirine, followed by an additional eight cycles of Epcoritamab alone, totaling twelve treatment cycles over about one year. Epcoritamab is given as a subcutaneous injection with a step-up dosing schedule in the first cycle and regular dosing in subsequent cycles. Loncastuximab Tesirine is administered intravenously during the first four cycles. The total participation duration in the study is approximately three years. During the trial, participants will be closely monitored through regular assessments for side effects such as cytokine release syndrome, neurotoxicity, fluid accumulation, and liver toxicity related to the study drugs. Researchers will measure treatment response rates, progression-free survival, and overall survival over up to 36 months. Participants will have scheduled visits and tests to evaluate safety and effectiveness throughout the study period.

CONDITIONS

Brief Title

Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma

Research Team

J

Juan Alderuccio, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here